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High Risk Plaque, High Risk Patient or High Risk Procedure?
A.R. Naylor1* and J. Golledge2
The Departments of Vascular Surgery at 1Leicester Royal Infirmary, Leicester, UK, and
2James Cook University, Townsville, Queensland, Australia
SAPPHIRE, a randomised trial of endarterectomy versus angioplasty in ’high-risk’ patients, concluded that angioplasty
was ’not inferior’ to surgery. This has subsequently been translated to mean that angioplasty was ’preferable’ or ’advisable’
in patients considered high-risk for surgery, with no further discrimination between symptomatic and asymptomatic in-
dividuals. Moreover, there have been suggestions that the accepted procedural risks may have to be increased in these pa-
tients. In fact, 71% of patients in SAPPHIRE were asymptomatic in whom there was an average 6% 30-day death/stroke
rate. At this level of risk, neither surgery nor angioplasty could ever prevent long-term stroke. The concept of identifying
high-risk patients is laudable, but they should be high risk for stroke (i.e. symptomatic). There is currently little systematic
evidence to include asymptomatic patients within this definition.
Keywords: Carotid stenosis; Stroke; Endarterectomy; Angioplasty.‘‘Perhaps we need to raise the bar a little bit in terms of
comparing angioplasty and endarterectomy in high-risk
patients. The idea is not that angioplasty and stenting has
to meet a standard of 6% risk in symptomatic patients
and 2e3% in asymptomatic patients. In fact, the bar is sub-
stantially higher than that’’
Sullivan1
The management of carotid artery disease remains
one of the most scrutinised, yet enduringly controver-
sial areas of medicine. The last 30 years have seen
three major randomised trials in symptomatic
patients, five in asymptomatic patients and ten (two
ongoing) comparing carotid endarterectomy (CEA)
with carotid angioplasty/stenting (CAS). The most
controversial is SAPPHIRE,2 whose findings have
been interpreted in a number of different ways.
Enthusiasts have suggested that ‘‘when CEA is not
feasible (in high-risk patients) and CAS is, patients
should undergo stenting regardless of the medical
risk’’.3 By contrast, alternative interpretation of the
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as CAS in SAPPHIRE-eligible patients’’ and that
‘‘asymptomatic patients should not be offered
protected stenting outside a controlled randomised
trial’’.4,5 How can these opposing viewpoints be
reconciled?
SAPPHIRE was the first randomised carotid trial to
specifically target recruitment from patients deemed
‘high-risk’. In itself, that is a perfectly reasonable
aim and an important question to answer. A similar
strategy was used in the EVAR II study comparing en-
dovascular repair with conservative management in
patients deemed unfit for open aneurysm surgery.6
However, key to understanding the SAPPHIRE con-
troversy is the definition of what constitutes ‘high-
risk’. Are we talking about a plaque that is high risk
for causing thrombo-embolic stroke, a patient who
through pre-existing co-morbidity is high-risk for
surviving surgical intervention or a procedure that be-
cause of anatomical or other hostile features makes
surgical intervention more hazardous? It is important
to be clear which definition applies if the results of
SAPPHIRE are to be correctly and safely applied
into clinical practise.
To qualify for entry into SAPPHIRE, patients had
to be either; (a) symptomatic with a 50e99% stenosis
or (b) asymptomatic with an 80e99% stenosisrved.
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factor from the following; clinically significant cardiac
disease, severe pulmonary disease, contralateral
occlusion, recurrent laryngeal nerve palsy, neck
irradiation, recurrent stenosis after CEA or be aged
>80 years.2
The significance of each of these factors will de-
pend on the mode of presentation. Most symptomatic
patients (especially those with recent symptoms) will
fall into the category of having a ‘high-risk plaque’
and surgeons would generally agree that the presence
of severe cardiac or respiratory disease does increase
the operative risk (i.e. a high-risk patient also), while
the presence of a contralateral recurrent laryngeal
nerve palsy would make CEA a more ‘high-risk pro-
cedure’. However, the key determinant in continuing
to consider intervention is the simple fact that the pa-
tient was symptomatic. In this respect, Sullivan’s sug-
gestion that the ‘bar might be lifted’ in selected,
symptomatic patients may be reasonable. Conversely,
most clinicians would view the same adverse risk sce-
nario in an asymptomatic patient as being much less
compelling regarding the continuing need to inter-
vene. This is particularly relevant in patients aged
>75 years (ACST showed no evidence of benefit re-
garding CEA) and female patients.7 Although ACST
initially claimed that CEA conferred a significant
benefit in women (unlike ACAS which showed no
benefit in women7), the long-term data did not in-
clude the operative risk.8 When the operative risk
was included, the apparent long-term benefit con-
ferred by CEA disappeared, although it is likely
that younger women will gain some benefit after
a longer period of follow-up.9,10 Accordingly, the
available evidence suggests that it would be inappro-
priate to label any asymptomatic female patient as
being ‘high-risk’.
So who were randomised in SAPPHIRE and how
did they fare? The data shows that 71% of the patients
randomised in SAPPHIRE (i.e. the vast majority) were
asymptomatic, while a quarter had recurrent, as op-
posed, to primary atherosclerotic disease.2 In the
asymptomatic patients, the 30-day death/stroke rate
was 5.8% following CAS and 6.1% after CEA (i.e. av-
eraging about 6%). At this level of risk, all potential
benefit from any intervention ceases. Accordingly,
clinicians who cite the asymptomatic trials as being
a justification for intervention cannot do so with the
level of risk observed in SAPPHIRE.
Some will argue that ‘they can do better’, but the
available data do not support this. One of the rea-
sons for terminating SAPPHIRE prematurely was de-
clining recruitment because ‘several nonrandomized
stent registries had become available’. In fact, sevenEur J Vasc Endovasc Surg Vol 32, November 2006have now released their data.11 None of these
‘high-risk stent registries’ have been published in
peer-reviewed journals (most of the data has to be
obtained from the Internet), all were industry funded
with the principle aim of gaining approval for spe-
cific stents/protection devices and almost all had se-
lection criteria similar to SAPPHIRE. However, the
one common feature is that all have used their re-
sults to advocate a policy of CAS in ‘high-risk’ pa-
tients. No one has interpreted the available data in
an alternative manner and suggested that perhaps
some of these ‘high-risk’ patients did not require
any intervention at all!
Closer scrutiny confirms that, just like SAPPHIRE,
50e83% of patients in the seven registry studies
were asymptomatic, while 20e40% had recurrent ste-
noses after CEA. Two did not release 30-day death/
stroke data (MAVERiC and CREATE). Three
published 30-day death/stroke rates >6% (ARCHeR,
CHRS, SECURiTY) and only one (CABERNET) re-
ported a 30-day death/stroke rate <4%. For reasons
highlighted previously, these data cannot be used to
support the uncritical use of CAS in ‘high-risk asymp-
tomatic patients’ as the long-term benefit will not
accrue with that level of risk. Accordingly, it would
be inappropriate to adopt Sullivan’s recommendation
that we should accept a higher procedural risk (for
both CEA and CAS) in the asymptomatic ‘high-risk’
patient, and, definitely not, in patients who were either
female or aged >75 years.
The principle underlying the SAPPHIRE trial was
good; unfortunately the evidence suggests that the
wrong patients were randomised. Surely, the term
‘high-risk’ must (almost exclusively) apply to symp-
tomatic patients. Moreover, in the environment of in-
ter-disciplinary ‘turf-wars’ about who should perform
CAS and a pre-occupation with treating vast numbers
of asymptomatic patients, we are actually failing to
identify and treat the most important high-risk group
of all; the ‘lost tribe’. The term ‘lost tribe’ refers to a co-
hort of symptomatic patients who (in the current envi-
ronment) never reach our vascular or interventional
services. Previously, we were taught that the risk of
stroke after TIA or minor stroke was 1e2% at 7 days
and 2e4% at one month.12 However, these data were
derived from populations of patients who were re-
cruited weeks or months after the index event, by which
time some would already have suffered a stroke and not
be randomised or followed up. Recent work from the
Oxford Vascular Study suggests that the true risk of
stroke after TIA or minor stroke may be as high as 8e
12% at seven days, 12e15% at 30-days and 17e19% at
three months.13 The ‘lost tribe’ represent the true defini-
tion of ‘high-risk’ but we very rarely see them.
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‘high-risk’? Obviously a minority will be, but our
problem remains identifying the 10e15% destined to
suffer a stroke amongst the 85e90% who won’t. Ac-
cordingly, targeting CAS on asymptomatic patients
because of some clinical factor that makes them
(otherwise) high-risk for CEA will do little to reduce
the overall risk of stroke in our communities. An
alternative reworking of the SAPPHIRE data shows
that with a procedural risk of 6%, only 22 strokes
will be prevented at five years by treating 1000
patients!
Inevitably, more resources must be targeted at
identifying asymptomatic patients with a ‘high-risk
plaque’. Although this has been a ‘holy grail’ for de-
cades, insufficient resources have been allocated to
undertake systematic large scale studies. In the
United Kingdom (towards the turn of the millen-
nium), approximately £120 million was spent annu-
ally on cancer research, £43 million on heart disease,
but only £2.5 million was spent on stroke.14 Stroke
has always been the poor relation in terms of re-
sources and political priority.
Some studies have evaluated plasma markers in
symptomatic patients, but few have been undertaken
in an asymptomatic cohort of any size. Given the fi-
nancial restraints alluded to above and the length of
follow-up required, this will only be rectified by going
‘international’ and collaborating together. From the
‘symptomatic literature’, elevated levels of C-reactive
protein, fibrinogen and plasma MMP-9 have been pre-
dictive of increased risk for stroke and in identifying
unstable plaques15,16 and might be considered suit-
able for prospective evaluation in asymptomatic
patients. Advances in MR imaging now enables iden-
tification of luminal thrombus and may rejuvenate
plaque morphology studies.17 MR evidence of overly-
ing luminal thrombus in an asymptomatic patient
would certainly be a compelling reason for interven-
ing prophylactically. Finally, preliminary studies sug-
gest that the detection of microembolisation (using
transcranial Doppler) may predict high-risk asymp-
tomatic patients who should be considered for sur-
gery. Microembolisation was studied in 319 patients
with 60e99% asymptomatic stenoses who were then
followed up for two years.18 Patients with evidence
of embolisation were significantly more likely to suf-
fer a stroke during the first year of follow-up (15%
versus 1%). Similar studies are nearing completion
in Europe and may enable better case selection in
asymptomatic patients in the future.
In summary, the concept of identifying or prioritis-
ing ‘high-risk’ patients for treatment is laudable.
However, Alhaddad’s recommendation that CASshould be considered in all ‘high risk’ patients
irrespective of the medical risk cannot be sustained3
and certainly not in asymptomatic individuals. The
same caveat applies to proponents of CEA. Accord-
ingly, while Sullivan may be right in advocating ‘rais-
ing the bar’ in selected, symptomatic patients with
recent onset symptoms and adverse clinical or imag-
ing features, the same cannot be said for asymptom-
atic patients. Until we can identify predictors of
increased stroke risk in asymptomatic patients, the
term ‘high risk’ should only be applied to patients
who are symptomatic.
Finally, irrespective of any debate about which
asymptomatic patients should be treated, whether
CEA or CAS is safer, how CEA should be performed,
or who should perform CAS, ALL of these pale into
insignificance (regarding the magnitude of stroke
prevention) when compared with the effect of delay
in treating symptomatic patients with severe carotid
artery disease.
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